Linaclotide is currently undergoing Phase 2b clinical testing in patients with IBS-C and CC. In earlier clinical studies, linaclotide demonstrated improved bowel function in patients with IBS-C and CC. These studies also showed linaclotide was well tolerated with a low incidence of adverse events. Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism distinct from previously developed products for IBS-C and CC. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure. Microbia and Forest intend to initiate Phase 3 studies in the second half of 2008.
"Joining forces with Forest is the best way to maximize linaclotide's value for patients and investors," said Peter Hecht, Microbia's Chief Executive Officer. "Forest uniquely combines world-class primary care commercial capabilities and an entrepreneurial and collaborative culture. Our companies share a common vision and commitment for getting linaclotide to IBS-C and CC sufferers."
About Irritable Bowel Syndrome (IBS)
One out of six adults in developed countries suffers from IBS, a
chronic condition marked by abdominal pain and disturbed bowel function.
IBS accounts for 12% of adult visits to primary care physicians and is the
most common disorder diagnosed by gastroenterologists. Health care costs
associated with IBS exceed $25 billion annually. IBS patients fall into
three subgroups- constipation-predominant (IBS-C), diarrhea-predominant
(IBS-D), and alternating (IBS-A)-and 30% to 40% of these patients suffer
from IBS-C. There are currently few available ther
|SOURCE Forest Laboratories, Inc.; Microbia, Inc.|
Copyright©2007 PR Newswire.
All rights reserved